CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG1114 (clinicaltrials.gov NCT No: NCT01399372)
Title:PHASE II RANDOMIZED STUDY OF RITUXIMAB, METHOTREXATE, PROCARBAZINE, VINCRISTINE, AND CYTARABINE WITH AND WITHOUT LOW-DOSE WHOLE-BRAIN RADIOTHERAPY FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Principal Investigator:Ivo Tremont
Treatment Agent:Cytarabine; Methotrexate; Procarbazine; Radiation; Rituximab; Vincristine
Study Status:Open
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS; Lymphoma
Phase of Study:Phase II
Treatment Agents:Cytarabine
Methotrexate
Procarbazine
Radiation
Rituximab
Vincristine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NCI/NRG Oncology
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ivo Tremont
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults